D. C. GÜVEN Et Al. , "Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy," SUPPORTIVE CARE IN CANCER , vol.29, no.9, pp.5417-5423, 2021
GÜVEN, D. C. Et Al. 2021. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. SUPPORTIVE CARE IN CANCER , vol.29, no.9 , 5417-5423.
GÜVEN, D. C., AKSUN, M. S., ŞAHİN, T. K., AKTEPE, O. H., YILDIRIM, H. Ç., TABAN, H., ... Ceylan, F.(2021). Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. SUPPORTIVE CARE IN CANCER , vol.29, no.9, 5417-5423.
GÜVEN, DENİZ Et Al. "Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy," SUPPORTIVE CARE IN CANCER , vol.29, no.9, 5417-5423, 2021
GÜVEN, DENİZ C. Et Al. "Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy." SUPPORTIVE CARE IN CANCER , vol.29, no.9, pp.5417-5423, 2021
GÜVEN, D. C. Et Al. (2021) . "Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy." SUPPORTIVE CARE IN CANCER , vol.29, no.9, pp.5417-5423.
@article{article, author={DENİZ CAN GÜVEN Et Al. }, title={Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy}, journal={SUPPORTIVE CARE IN CANCER}, year=2021, pages={5417-5423} }